Spain's Faes aims for Asian drug launch, OTC selloff; Jury adds $90M punitive award to Teva, Baxter tab;

@FiercePharma: Weak cancer meds, Tamiflu take bite out of Roche sales. Story | Follow @FiercePharma

> Spain's Faes Farma plans to launch its bilastine allergy drug in Asia and sell off OTC drugs to offset the sales hit from government cost-cutting. News

> A jury levied $90 million in punitive damages against Teva Pharmaceutical Industries ($TEVA) and Baxter International ($BAX) in the third trial over a hepatitis C outbreak linked to the anesthetic propofol. Story

> Onyx Pharmaceuticals shares climbed for the second day in a row after a legal settlement with Bayer prompted BMO Capital Markets to upgrade the stock to "outperform." Item

> Russia expanded its essential drugs list with a number of branded cancer drugs, including Novartis' ($NVS) Afinitor, Eli Lilly's ($LLY) Alimta, Bayer's Nexavar and AstraZeneca's ($AZN) Iressa. Article

> Belgian distributor Omega Pharma tossed its full-year forecast after turning in weak third-quarter sales. Report

> Standard & Poor's rated Mylan's ($MYL) proposed $2.25 billion senior credit facility at BBB. Story

> AstraZeneca said it bought back 500,256 shares at a price of 2979 pence per share, as part of its ongoing stock repurchase program. Report

Biotech News 

@FierceBiotech: Medivation chief amps up rhetoric on Ph3 prostate cancer drug. Story | Follow @FierceBiotech

@RyanMFierce: Bi-specific antibody upstart Oncobiologics charts expansion in new NJ labs. Report | Follow @RyanMFierce

@MaureenFierce: Option-based deals: How biotechs and big pharmas share R&D risks. Article  | Follow @MaureenFierce

> Medivation chief amps up rhetoric on Ph3 prostate cancer drug. Item

> Depomed shares crater on another Phase III miss for hot-flash drug. Story

And Finally... Pfizer has teamed up with Humana to track care and costs for elderly patients with chronic pain, cardiovascular problems and Alzheimer's disease. Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.